The CD94/NKG2C-expressing NK cell subset is augmented in chronic lymphocytic leukemia patients with positive human cytomegalovirus serostatus

Viral Immunology

Volumn 22, Issue 5, 2009, Pages 333-337

  Petersen, Line ^a   Roug, Anne S ^b   Skovbo, Anni ^a   Thysen, Anna H ^a   Eskelund, Christian W ^a   Hokland, Marianne E ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL;

ADULT; AGED; AGED, 80 AND OVER; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D;

HUMAN HERPESVIRUS 5; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70350123591     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0032     Document Type: Article

References (24)

1. Biron CA, Byron KS, and Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-1735.
2. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, and Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequencederived peptides by CD94=NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998;187:813-818.
3. Braud VM, Allan DS, O'Callaghan CA, et al.: HLA-E binds to natural killer cell receptors CD94=NKG2A, B and C. Nature 1998;391:795-799.
4. Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, and Devereux S: Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia 2008;22:1084-1087.
5. Chiorazzi N, Rai KR, and Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
6. Cordingley FT, Bianchi A, Hoffbrand AV, et al.: Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988;1:969-971.
7. Crough T, and Khanna R: Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009;22:76-98.
8. Diehl LF, Karnell LH, and Menck HR: The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999;86:2684-2692.
9. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, and Lopez-Botet M: Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004;104: 3664-3671.
10. Guma M, Budt M, Saez A, Brckalo T, Hengel H, Angulo A, and Lopez-Botet M: Expansion of CD94=NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood 2006;107:3624-3631.
11. Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, and Lopez-Botet M: Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94=NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006;194:38-41.
12. Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, and Dilber MS: Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003;17:1973-1980.
13. Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, and Eliopoulos GD: Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol 1996;96: 16-23.
14. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez- Botet M, and Geraghty DE: HLA-E is a major ligand for the natural killer inhibitory receptor CD94=NKG2A. Proc Natl Acad Sci USA 1998;95:5199-5204.
15. Lodoen MB, and Lanier LL: Viral modulation of NK cell immunity. Nat Rev Microbiol 2005;3:59-69.
16. Mela CM, and Goodier MR: The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1- infected individuals. J Infect Dis 2007;195:158-159; author reply 159-160.
17. Miller-Kittrell M, and Sparer TE: Feeling manipulated: cytomegalovirus immune manipulation. Virol J 2009;6:4.
18. Palmer S, Hanson CA, Zent CS, et al.: Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008;141:607-614.
19. Quinnan GV Jr, Kirmani N, Rook AH, et al.: Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrowtransplant recipients. N Engl J Med 1982;307:7-13.
20. Sivori S, Pende D, Bottino C, et al.: NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-1666.
21. Spaggiari GM, Carosio R, Pende D, et al.: NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol 2001;31:1656-1665.
22. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, and Weiss EH: Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLAE and prevents NK cell-mediated lysis. J Immunol 2000;164: 5019-5022.
23. Venema H, van den Berg AP, van Zanten C, van Son WJ, van der Giessen M, and The TH: Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol 1994;42:188-192.
24. Ziegler HW, Kay NE, and Zarling JM: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981;27:321-327.